Prosensa Holding Hops Over the Pond for Nasdaq Debut
Prosensa Holding B.V., of Leiden, the Netherlands, became the first European biotech company in 10 years to file for its initial public offering (IPO) on the Nasdaq to support development of its products for Duchenne's muscular dystrophy and other programs. It plans to raise about $78 million.
Prosensa's product pipeline is based on RNA-modulation, focusing on rare neuromuscular and neurodegenerative disorders with large unmet medical need.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter